Two years ago, the conversation about weight loss medication in Dubai was short: there were two injections and one old tablet. That is no longer true. There are now seven licensed options in the UAE, working through four different mechanisms, in injectable and tablet form, at very different price points and with very different safety profiles.
More choice is genuinely good news. It also makes the decision harder, and it means the question is no longer “which is strongest?” but “which one fits this particular patient?” A medicine that produces 20% weight loss is worthless to someone who cannot tolerate it, cannot afford it, or should not be taking it at all.
This article sets out every option as I would explain it in clinic — what it does, what it achieves, what it costs you in side effects, and who it actually suits.
Obesity in the UAE is a medical condition, not a failure of willpower
Roughly two in three adults in the UAE aged 18 to 69 are living with overweight or obesity, according to the national health survey data compiled by the World Obesity Federation. That is not a statistic about discipline. It is a statistic about an environment — a climate that discourages outdoor activity for much of the year, long working hours, abundant food delivery, and long commutes — acting on human biology that evolved to defend body fat.
There is a second point that matters specifically here. In South Asian, Arab and East Asian populations, metabolic risk begins at a lower body mass index than the thresholds derived from European populations. A person of South Asian origin can carry a significant burden of visceral fat, insulin resistance and fatty liver at a BMI that looks unremarkable on a chart. This is why I assess waist circumference, metabolic bloods and liver status rather than treating BMI as the whole story.
Obesity is now understood as a chronic, relapsing medical condition involving appetite regulation in the brain. That understanding is what made this generation of medicines possible.
Four mechanisms, seven medicines
Every licensed weight loss medicine works in one of four ways. Understanding which family a drug belongs to explains almost everything about how it behaves — including its side effects.
Group 1 — The incretin medicines (GLP-1 based)
Incretins are hormones your gut releases when you eat, which tell the brain you have eaten and slow the rate at which the stomach empties. These medicines are long-acting versions of those signals. They are the most effective class available, and four are now licensed.
Semaglutide (Wegovy, Ozempic) — a GLP-1 receptor agonist given as a once-weekly injection under the skin. Licensed for chronic weight management, and separately at different doses for type 2 diabetes.
Tirzepatide (Mounjaro, Zepbound) — acts on two receptors, GLP-1 and GIP. Adding the GIP signal appears to improve both appetite suppression and how the body handles fat and glucose. Also a once-weekly injection, and the most effective option currently available.
Oral semaglutide 25 mg (the Wegovy pill) — the same molecule as injectable semaglutide, formulated as a daily tablet. The Emirates Drug Establishment approved it for weight management and cardiovascular risk reduction, and it launched in the UAE in mid-2026. The trade-off is absorption: it must be taken on an empty stomach with no more than half a glass of water, and you must wait 30 minutes before eating, drinking or taking other medicines. That routine is not difficult, but it is unforgiving — skip it and the dose is largely wasted.
Orforglipron (Foundayo) — the newest and, for some patients, the most practically significant. Unlike everything above, it is not a peptide but a small molecule, which is why it survives digestion without special formulation. Approved by the FDA on 1 April 2026 and by the Emirates Drug Establishment in April 2026, reaching UAE pharmacies from May 2026. It is taken once daily with or without food, with no water restriction and no waiting period. For a patient who travels constantly, eats at irregular hours, or has simply failed to keep to the oral semaglutide routine, that difference matters more than a percentage point of average weight loss.
A note on language before we go further. None of these medicines “melts fat” or “burns” anything. They reduce appetite and food preoccupation and slow gastric emptying, so you eat less without the constant fight against hunger that makes conventional dieting fail.
Group 2 — The fat absorption blocker
Orlistat (Xenical) — the oldest medicine on this list and the only one that does not act on the brain at all. It inhibits pancreatic lipase in the gut, so roughly a third of the fat you eat passes through undigested. Taken three times daily with meals.
Its effect is modest, and it has an unusual property: the side effects are directly proportional to how much fat you eat. Eat a high-fat meal and you will know about it. Some patients describe this as an unpleasant but effective feedback loop, which is a fair characterisation.
Group 3 — The appetite suppressant combination
Phentermine/topiramate extended-release (Qsymia) — combines a sympathomimetic appetite suppressant with topiramate, an anti-epileptic that also reduces appetite through mechanisms that are not fully understood. Taken once daily in the morning. VIVUS launched it in the UAE in March 2025, making the Emirates the first country in the Middle East where it became available. It is the most effective non-incretin option — and it carries the most restrictive safety requirements of anything on this page.
Group 4 — The craving and reward combination
Naltrexone/bupropion sustained-release (Contrave) — combines an opioid receptor antagonist with an antidepressant that also acts on dopamine and noradrenaline. Together they act on the hypothalamic appetite centre and, importantly, on the brain’s reward pathway. Taken twice daily.
Its distinctive value is not the average weight loss figure. It is that it targets craving and reward-driven eating rather than hunger. The patient who is not especially hungry but cannot stop thinking about chocolate at 9pm is a different clinical problem from the patient who is ravenous at every meal, and Contrave was designed for the first.
What weight loss is realistic: the numbers, side by side
These are averages from the pivotal trials, in people who also received structured dietary and activity support. They are not head-to-head comparisons — the trials differ in population, duration and design — so read them as a guide to magnitude, not a league table.
| Medicine | Route | Average weight reduction |
|---|---|---|
| Tirzepatide (Mounjaro) 10–15 mg | Weekly injection | ~20–21% |
| Semaglutide (Wegovy) 2.4 mg | Weekly injection | ~15% |
| Oral semaglutide 25 mg | Daily tablet | ~17% |
| Orforglipron (Foundayo) 36 mg | Daily tablet | 12.4% |
| Phentermine/topiramate (Qsymia) 15/92 mg | Daily capsule | 9.8% |
| Naltrexone/bupropion (Contrave) 32/360 mg | Twice daily tablet | 6.1% |
| Orlistat (Xenical) 120 mg | Three times daily | ~5.8 kg |
Three honest caveats belong beside that table.
An average conceals a wide spread. Some people lose considerably more; a minority lose very little. Non-response happens, and it is biology rather than a moral failing — a reason to reassess rather than simply escalate the dose.
The trial participants all received structured support. The medicine was never the whole intervention, and it should not be in your case either.
Length of follow-up differs enormously. Orlistat’s figure comes from a four-year study, where most of the others report at around a year. XENDOS is worth knowing about for a second reason: over four years, orlistat plus lifestyle change reduced the incidence of type 2 diabetes from 9.0% to 6.2% — a 37% relative risk reduction. Modest weight loss sustained for a long time is not nothing.
What is coming next. Retatrutide, a triple agonist acting on GLP-1, GIP and glucagon receptors, reported Phase 3 results from the TRIUMPH programme in May 2026, with average weight reduction of approximately 28% at 80 weeks. It is not yet available for prescription. I mention it because patients ask — but it is not an option today.
Side effects: what each one actually costs you
This is where the medicines diverge most, and where the choice is usually made.
The incretin medicines
Gastrointestinal effects dominate: nausea, vomiting, diarrhoea and constipation. They are dose-dependent, most pronounced during dose escalation, and usually settle. Slow escalation, smaller meals, reduced fat and alcohol intake, and adequate hydration make a substantial difference. Discontinuation because of side effects occurred in roughly 4% to 11% of trial participants depending on the drug and dose.
Gallstones become more likely with rapid weight loss of any cause. Pancreatitis is rare but recognised, and warrants immediate assessment if severe abdominal pain develops. Loss of lean muscle mass accompanies weight loss on any of these — see losing weight without losing muscle.
One point specific to orforglipron: it may reduce the effectiveness of oral contraceptives, so contraception needs discussing before starting.
Orlistat (Xenical)
The side effects are almost entirely gastrointestinal and almost entirely dietary in origin: oily stools, urgency, flatus with discharge, and oily spotting. They are worst with high-fat meals and improve markedly on a genuinely low-fat diet.
The clinically important issue is absorption of fat-soluble vitamins — A, D, E and K. This deserves particular attention in the UAE, where vitamin D deficiency is already common despite year-round sunshine. Anyone on orlistat should take a multivitamin containing the fat-soluble vitamins, at bedtime or at least two hours from a dose, and have vitamin D checked and corrected. Severe liver injury has been reported very rarely.
Phentermine/topiramate (Qsymia)
This one requires the most careful conversation, and I do not soften it.
Pregnancy is the critical issue. Topiramate taken in the first trimester increases the risk of oral clefts — cleft lip and cleft palate — in the baby. Any woman who could become pregnant must use effective contraception throughout treatment, have a negative pregnancy test before starting and monthly thereafter, and stop the medicine immediately if pregnancy occurs. This is not a theoretical precaution.
In the CONQUER trial, at the top dose, common adverse effects included dry mouth (21%), pins and needles or tingling (21%), constipation (17%), insomnia (10%), dizziness (10%) and altered taste (10%). Depression-related events occurred in 7% and anxiety-related events in 8%, against 4% and 3% on placebo.
Other considerations: it raises heart rate; it can cause metabolic acidosis and kidney stones; it may impair concentration and word-finding in some people; and phentermine is a controlled substance, which affects prescribing and how you should handle travel with it. It is contraindicated in pregnancy, glaucoma, hyperthyroidism, and within 14 days of a monoamine oxidase inhibitor.
Naltrexone/bupropion (Contrave)
In the COR-I trial, nausea affected 30% of participants against 5% on placebo — the single most common reason for stopping. Headache, constipation, dizziness, vomiting and dry mouth were also more frequent. Blood pressure and heart rate rose transiently early in treatment, so both must be monitored.
Two things must be excluded before prescribing. Bupropion lowers the seizure threshold, so it is contraindicated in anyone with a seizure disorder, an eating disorder such as bulimia or anorexia nervosa, or abrupt withdrawal from alcohol, benzodiazepines or antiepileptics. Naltrexone blocks opioid receptors, so it cannot be used by anyone taking opioid painkillers, and it will precipitate withdrawal in someone opioid-dependent. It also carries the antidepressant class warning about suicidal thoughts and behaviour, particularly in younger adults — though COR-I itself found no increase in depression or suicidality against placebo. It is contraindicated in uncontrolled hypertension and within 14 days of a monoamine oxidase inhibitor.
A practical point for Ramadan
Fasting on any of these requires planning, and the issues differ by drug. On an incretin, delayed gastric emptying plus reduced daylight fluid intake plus a large iftar meal combine badly. On orlistat, the timing shifts to meals rather than clock hours. On Qsymia, a morning dose becomes a suhoor dose, and dehydration raises the kidney stone risk. Dose timing and meal structure should be discussed before Ramadan begins, not during the first difficult week.
Who each one actually suits
This is the part that a price list cannot tell you.
Tirzepatide — the highest average weight loss, so the first consideration where the weight-related health burden is greatest: substantial obesity, type 2 diabetes, severe sleep apnoea, significant fatty liver. Requires a weekly injection and the highest ongoing cost.
Semaglutide — well-established, with the largest body of cardiovascular outcome evidence behind the molecule. A strong choice where cardiovascular risk is the dominant concern.
Oral semaglutide — for the patient who will not inject, and who can reliably keep to the empty-stomach routine. Adherence discipline is the deciding factor.
Orforglipron (Foundayo) — for the patient who will not inject and whose life does not accommodate a rigid dosing routine: frequent travellers, shift workers, irregular meal times. Simplicity is its clinical advantage.
Orlistat (Xenical) — for the patient who wants a non-systemic option that does not act on the brain at all, who is willing to eat a low-fat diet, or for whom cost is the binding constraint. Also worth considering where there is impaired glucose tolerance, given the XENDOS diabetes-prevention finding.
Phentermine/topiramate (Qsymia) — the most effective non-incretin option, for the patient who cannot use or cannot afford an incretin, provided pregnancy risk can be managed rigorously and there is no glaucoma, hyperthyroidism or significant anxiety or mood disorder.
Naltrexone/bupropion (Contrave) — for craving-driven and reward-driven eating rather than hunger-driven eating; for evening grazing and emotional eating patterns. There is a further practical point: bupropion is also used for smoking cessation, so the patient trying to stop smoking and control weight simultaneously is a genuinely good fit. Not for anyone on opioids or with a seizure risk.
And for some patients, none of them. Where weight gain is driven by an untreated thyroid disorder, by obstructive sleep apnoea, by a medication that promotes weight gain, or by an eating disorder, the right first step is to treat that — not to add an appetite suppressant on top.
Who should not take these medicines
The incretin medicines should be avoided or used only after specialist discussion if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; a history of pancreatitis; severe gastroparesis; pregnancy, breastfeeding or plans to conceive in the near term; or active untreated diabetic retinopathy.
The drug-specific exclusions above apply to the others: pregnancy and glaucoma for Qsymia, seizure risk and opioid use for Contrave, chronic malabsorption and cholestasis for Xenical. None of these medicines should be combined with another in the same class, and incretins should never be taken together.
A legitimate prescription requires a consultation, a history, an examination and baseline investigations. An online form is not an assessment, and a medicine sourced without one carries risks that have nothing to do with the drug itself.
One further note on availability. Registration and supply in the UAE change quickly — three of the medicines on this page were not available here two years ago. What a pharmacy can dispense in a given month is worth confirming at the time rather than assuming from an article.
What proper treatment actually looks like
In my clinic, starting a weight management medicine involves:
A baseline assessment. Full history including previous weight loss attempts, eating pattern, medications that promote weight gain, sleep and screening for obstructive sleep apnoea, and a mental health enquiry. Examination including waist circumference and blood pressure.
Baseline investigations. HbA1c and fasting insulin, full lipid profile, liver function and assessment for fatty liver, thyroid function, kidney function, vitamin D. In selected patients, body composition analysis so we can track fat and lean mass separately rather than watching a single number on a scale.
Drug-specific checks before starting. A pregnancy test and a contraception plan before Qsymia, repeated monthly. Blood pressure and a seizure, eating disorder and opioid history before Contrave. Vitamin D status and a fat-soluble vitamin supplement plan before Xenical. A contraception discussion before orforglipron.
Structured dose escalation with review at each step, adjusted to your tolerance rather than a fixed schedule.
Regular review — typically at 4, 12 and 24 weeks, then quarterly — assessing weight, body composition including muscle mass and fat mass as well as visceral fat, blood pressure, metabolic markers, side effects and, importantly, whether the nutritional and resistance training foundation is actually in place.
An exit and maintenance plan agreed at the start, not improvised at the end. This matters more than almost anything else, and it is the subject of a separate article: why weight comes back after stopping.
Frequently asked questions
Which is more effective for weight loss, Mounjaro or Ozempic?
In comparative trial data, tirzepatide produces greater average weight reduction than semaglutide. But “more effective on average” does not mean “better for you” — tolerance, other medical conditions, availability and cost all matter, and some people respond very well to semaglutide.
What is Foundayo, and how is it different from the Wegovy pill?
Foundayo is the brand name for orforglipron, a once-daily GLP-1 tablet approved by the Emirates Drug Establishment in April 2026. Both are oral GLP-1 medicines, but orforglipron is a small molecule rather than a peptide, so it can be taken with or without food and with no water restriction or waiting period. Oral semaglutide must be taken on an empty stomach with a small amount of water, followed by a 30-minute wait. In trials, oral semaglutide produced slightly greater average weight loss; orforglipron is considerably easier to take correctly.
Is a weight loss pill as effective as an injection?
Not quite, on average. The oral GLP-1 medicines produced around 12–14% mean weight reduction in their trials, against roughly 15% for injectable semaglutide and 20% for tirzepatide. But a tablet you take consistently will outperform an injection you abandon, so the honest answer depends on you rather than on the pharmacology.
Is Qsymia or Contrave safer than the GLP-1 injections?
Not straightforwardly — they have different risks rather than fewer. Qsymia carries a significant risk of birth defects if taken in pregnancy and requires monthly pregnancy testing in women who could conceive. Contrave cannot be used by anyone taking opioid medication or at risk of seizures. The GLP-1 medicines have their own exclusions. “Safer” only means anything once your own history is on the table.
Does Xenical still have a place now that the newer medicines exist?
Yes, for some patients. Its weight loss effect is modest, but it acts only in the gut rather than on the brain, it is the least expensive option, and in a four-year trial it reduced progression to type 2 diabetes by 37%. It requires a genuinely low-fat diet and supplementation of the fat-soluble vitamins.
How much weight will I lose in the first month?
Usually little, and that is expected. The first weeks are spent escalating the dose gradually to limit side effects. Meaningful weight change typically begins from around weeks 8 to 12. Judging the medicine at four weeks is judging it before it has started.
Do I need a prescription for weight loss medication in the UAE?
Yes — all of them. These are prescription-only medicines requiring assessment by a licensed physician, and phentermine, one component of Qsymia, is additionally a controlled substance. Products obtained outside that route may be counterfeit, incorrectly dosed or improperly stored.
Can I take weight loss medication while fasting in Ramadan?
Many patients do, safely, with planning — but the adjustments differ by medicine. Dose timing, meal structure and hydration should be reviewed before Ramadan starts, and anyone with diabetes on additional glucose-lowering medication needs a specific plan.
Talk it through properly. Obesity medicine works best when the medicine is one part of a plan that includes nutrition, resistance training, monitoring and a maintenance strategy. To discuss whether treatment is appropriate for you, book a consultation with Dr. Ali Aldibbiat, Consultant Endocrinologist, at Newcastle Vitality Clinic, Jumeirah.